Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain

Brain Research
Y OidaH Hara

Abstract

Rifampicin, an antibacterial drug, is highly effective in the treatment of tuberculosis and leprosy. Recently, it has been reported to have neuroprotective effects in in vitro and in vivo models. This study was designed to elucidate its neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity (known as an in vivo mouse model of Parkinson's disease). Mice were injected intraperitoneally (i.p.) with MPTP (10 mg/kg) four times at 1-h intervals, and brains were analyzed 3 or 7 days later. Rifampicin at 20 mg/kg (i.p., twice) had protective effects against MPTP-induced neuronal damage (immunohistochemical changes in tyrosine hydroxylase) in both the substantia nigra and striatum. Rifampicin also protected against the MPTP-induced depletions of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) in the striatum. The maximal concentrations of rifampicin between 30 and 240 min after a single rifampicin injection (20 mg/kg, i.p.) were 2.6 microM (at 30 min) in plasma and 0.77 microM (at 60 min) in striatum. Next, the effects of rifampicin on oxidative stress [lipid peroxidation in mouse brain homogenates and free radical-scavenging activity against diphenyl-p-pic...Continue Reading

References

Mar 1, 1978·Clinical Pharmacokinetics·G Acocella
Feb 1, 1989·Journal of Neurochemistry·D T DexterC D Marsden
Sep 1, 1994·Journal of Neurochemistry·M GerlachM B Youdim
Jan 1, 1994·Methods in Enzymology·J S BeckmanJ P Crow
Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·D T DexterC D Marsden
May 1, 1993·The Journal of Antimicrobial Chemotherapy·T MindermannO Gratzl
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Dec 1, 1996·Neurology·P Jenner, C W Olanow
Oct 17, 1998·Nature·E LeroyM H Polymeropoulos
Mar 23, 2000·Molecular Pharmacology·A S HerrT Rein
Oct 31, 2001·Brain Research·T ArakiY Imai
Dec 13, 2003·Brain Research·Burak YulugMathias Bähr
Jan 30, 2004·EMBO Reports·Takahiro TairaHiroyoshi Ariga
Mar 12, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hijiri WatanabeTsutomu Araki
Apr 3, 2004·Journal of Chromatography. a·Ignacio CallejaMaría Carmen Dios-Viéitez
Apr 17, 2004·Science·Enza Maria ValenteNicholas W Wood
Nov 16, 2004·Neuron·Coro Paisán-RuízAndrew B Singleton

❮ Previous
Next ❯

Citations

Jul 24, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Wei BiEnxiang Tao
Jul 25, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yu-bing DaiJan-Åke Gustafsson
Jun 7, 2014·Brain Research Bulletin·Burak YulugWolf Rüdiger Schabitz
Oct 24, 2009·Neurochemical Research·Baohua ChengXuewen Zhang
Aug 1, 2009·Biochemical and Biophysical Research Communications·Kenichi KakefudaHideaki Hara
Nov 23, 2007·Experimental Eye Research·Yuichi ChikaraishiHideaki Hara
Apr 7, 2007·Cellular & Molecular Biology Letters·Srinivasagam Raja SankarManickam Ramanathan
Sep 28, 2014·European Journal of Pharmacology·Saori TsujiiHideaki Hara
Jun 13, 2015·Assay and Drug Development Technologies·Adeola ShoboThavendran Govender
Feb 27, 2020·Antioxidants & Redox Signaling·Ana Mafalda GonçalvesNuno Empadinhas
Feb 16, 2017·Clinical Drug Investigation·Nicholas Zareifopoulos, George Panayiotakopoulos
Apr 6, 2019·Advances in Pharmacological Sciences·Adaze Bijou EnogieruOkobi Eko Ekpo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.